Share this page:
Dicerna was incorporated in Delaware in October 2006.
Dicerna’s headquarters are located at 33 Hayden Avenue, Lexington, MA 02421. The main telephone number is (617) 621-8097.
Dicerna’s stock is traded on the NASDAQ Global Market under the symbol DRNA. The company’s initial public offering (IPO) was on January 29, 2014.
Dicerna’s transfer agent is:
American Stock Transfer & Trust, LLC.
6201 15th Avenue
Brooklyn, NY 11219
Shareholder Services: (800) 937-5449
If your shares are held in your name, you must contact our transfer agent, American Stock Transfer & Trust, LLC. If your shares are held in street name, you must contact your broker to update your address.
Dicerna’s fiscal year ends on December 31st.
Dicerna’s legal counsel is:
Goodwin Proctor LLP
601 Marshall Street
Redwood City, CA 94063
Dicerna’s independent auditor is:
Deloitte & Touche LLP
200 Berkeley St #400
Boston, MA 02116
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of RNAi-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases.